| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/18/2002 | WO2001041756A3 Method and composition for treatment of ischemic neuronal reperfusion injury |
| 07/18/2002 | WO2001039766A3 Screening invertebrate pheromones for therapeutic activity |
| 07/18/2002 | WO2001032217A3 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 07/18/2002 | WO2001008682A3 Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats |
| 07/18/2002 | WO2001006991A9 Oil-in-water emulsion with improved stability |
| 07/18/2002 | WO2000078972A9 Regulation with binding cassette transporter protein abc1 |
| 07/18/2002 | US20020095135 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| 07/18/2002 | US20020095108 Photoreduction method for hemoglobin-visicle |
| 07/18/2002 | US20020095041 Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| 07/18/2002 | US20020095039 Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| 07/18/2002 | US20020095036 Synthesis of temozolomide and analogs |
| 07/18/2002 | US20020095035 For treating neoplasms, atherosclerosis, and chronic inflammatory diseases |
| 07/18/2002 | US20020095033 Monocyclic L-nucleosides, analogs and uses thereof |
| 07/18/2002 | US20020095002 Process for removing bile salts from a patient and alkylated compositions thereor |
| 07/18/2002 | US20020095001 Administering a compound selected from histamine, histamine dihydrochloride, histamine diphosphate, other histamine salts, esters, prodrugs, H2 receptor agonists, serotonin, NADPH oxidase inhibitor, and 5HT agonist to cure skin damage |
| 07/18/2002 | US20020095000 Treatment of dry eye syndrome |
| 07/18/2002 | US20020094999 Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer's disease and dementias |
| 07/18/2002 | US20020094998 Methods and compositions for treatment of ocular neovascularization and neural injury |
| 07/18/2002 | US20020094996 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases |
| 07/18/2002 | US20020094994 Pyrrolidine carboxylic Acid or ester derivatives are useful for treating alpha 4 beta 1 mediated cell adhesion |
| 07/18/2002 | US20020094992 Administering growth hormone secretagogue which is 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridin-5-yl)1-(R)-benzyloxymet hyl-2-oxo-ethyl)-isobutyramide, salt or prodrug |
| 07/18/2002 | US20020094991 Methods and compositions for treating microtubule-mediated viral infections and lesions |
| 07/18/2002 | US20020094990 Administering a polyamine compound to a human or non-human animal in need of antiviral, antipsoriasis, or antiretroviral therapy |
| 07/18/2002 | US20020094988 Administering to a male patient a combination of sildenafil citrate and papaverine hydrochloride(papaverine hydrochloride administered enternally) to treat male erectile dysfunciton |
| 07/18/2002 | US20020094987 Amide or thioamide substituted benzimidazole or quinoxaline derivatives; therapeutic utility via inhibition of tumor necrosis factor or phosphodiesterase |
| 07/18/2002 | US20020094986 Combination treatment for depression, anxiety and psychosis |
| 07/18/2002 | US20020094985 Differential delivery of nitric oxide |
| 07/18/2002 | US20020094983 Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| 07/18/2002 | US20020094981 Ophthalmic compositions for treating ocular hypertension |
| 07/18/2002 | US20020094980 Preparing 1,1-dioxo-2-phenyl-3-carboxy-4-phenyl-1,2-benzo(e)-thiazines by a five-step process starting with a (2-(methyl-oxycarbonyl-)phenyl-sulfonamido-)benzene; alkylation; cyclization; hydroxylation; esterification and coupling |
| 07/18/2002 | US20020094979 Use of 5HT-6 antagonists |
| 07/18/2002 | US20020094975 Effective to block sensory and motor functions of a nerve(s) at the site of administration; treating all categories of pain - acute or chronic, local or general; interfering with the nerve(s) propagating such pain |
| 07/18/2002 | US20020094973 Treating an immune-mediated disorder by administering a gold compound and a corticosteroid; antiinflammatory agents; antiproliferative agents; skin disorders; side effect reduction |
| 07/18/2002 | US20020094971 Hyperglucemic, antidiabetic agents comprising a granulated starch having a reduced surface available for enzymatic degradation to delay production of reducing sugars; oral time-release agents; surgical patients; athletes |
| 07/18/2002 | US20020094970 Compositions and methods for treating an arthritic condition |
| 07/18/2002 | US20020094969 Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
| 07/18/2002 | US20020094967 Polynucleotide |
| 07/18/2002 | US20020094963 Benzimidazole derivatives |
| 07/18/2002 | US20020094961 Derivatives of polyene macrolides and preparation and use thereof |
| 07/18/2002 | US20020094960 Specifically unipolar depression, treatment-refractory depression, resistant depression, anxious depression and dysthymia; 2-sulfamatomethyltetrahydropyrans and sulfamato-methylcyclohexanes, e.g. topiramate |
| 07/18/2002 | US20020094959 By injecting a biocompatible solution, with a given intrinsic viscosity, similar to a fatty acid mixture normally present in a healthy fat pad; treating heel pain |
| 07/18/2002 | US20020094958 Administering peptidyl diazomethylketones, peptidyl semicarbazones, and diazoacetyl peptidyl alkyl esters of given formula; selective antagonists for cathepsin enzymes; treating neurodegenerative disorders |
| 07/18/2002 | US20020094956 As well as animal model for kidney disease, a mouse that does not express a normal collagen type 4 composition in the glomerular basement membrane |
| 07/18/2002 | US20020094950 Preselected enzyme cleavage points are stable in blood but are cleavable within cells; use in drug delivery such as of antitumor agents |
| 07/18/2002 | US20020094948 To treat anemias or hemodialysis patients; individual dosage forms |
| 07/18/2002 | US20020094947 By administering with the excitatory opioid receptor antagonist nalmefene |
| 07/18/2002 | US20020094524 Preventing preferential viral disease; obtain human, administer an antagonist of neurokinin receptors, monitor humans for reduced viral activity |
| 07/18/2002 | US20020094440 Implant with coating of copolymer of vinylidenefluoride (VDF) and/or tetrafluoroethylene (TFE) with another monomer in amounts effective to reduce thrombosis and/or restenosis when such stents are used in, e.g. angioplasty procedures |
| 07/18/2002 | US20020094351 Administering wikstromol ( 4,4,8-trihydroxy-3, 31-dimethoxyliganan-9, 91-olide) to the patient for the prevention of hepatotoxicity |
| 07/18/2002 | US20020094349 Administering an extract of Melothria indica Lou (perennial barbaceous vine) to the leukemia cells and prostate cancer cells; solvent extraction and chromatographic purification |
| 07/18/2002 | US20020094347 A neuro-active molecule, other than dopamine, within a microsphere comprising a biocomatible polymer having kinetic characteristics that may be manipulated to allow for the permeation of drug through polymer at controlled rate |
| 07/18/2002 | US20020094345 For treatment of allergic diseases and/or disorders; composition does not contain a leukotriene antagonist |
| 07/18/2002 | US20020094342 Contacting skin with skin treatment composition having concentration of 1-(3-methoxybenzyl)-3-substituted thiourea compound effective for inhibiting free radical generation |
| 07/18/2002 | US20020094340 Chlamydia antigens and corresponding dna thereof |
| 07/18/2002 | US20020094337 Prevention of recurrent viral disease |
| 07/18/2002 | US20020094324 Gene therapy for restenosis using an adenoviral vector |
| 07/18/2002 | US20020094323 Administration of reactive oxygen species inhibitor or scavenger and at least one monocyte maturation-promoting agent |
| 07/18/2002 | US20020094318 Dispersible dry powder of a therapeutic agent such as insulin with an aerogel particle which is soluble in human pulmonary surfactant, such as sugars and carbohydrates |
| 07/18/2002 | DE10102053A1 Piperazinylcarbonyl-quinoline and piperazinylcarbonyl-isoquinoline derivatives useful for treatment of e.g. schizophrenia, psychoses, depression, Parkinson's disease and Alzheimer's disease |
| 07/18/2002 | DE10102050A1 Food, nutritional supplement, feed or medicament preparations containing conjugated cis/trans-octatrienoic acid, useful e.g. for reducing food intake, improving food utilization or treating cancer or diabetes |
| 07/18/2002 | DE10101917A1 Verwendung von Chromanen Use of chromans |
| 07/18/2002 | DE10065475A1 Use of intermediate-conductance potassium channel proteins for the diagnosis, prevention and treatment of disorders associated with disturbed keratinocyte activity, especially psoriasis |
| 07/18/2002 | DE10064312A1 Cholinpyruvat, Verfahren zu dessen Herstellung, Cholinpyruvat enthaltende Formulierung sowie deren Verwendung Choline pyruvate, containing process for the production thereof, choline pyruvate formulation and the use thereof |
| 07/18/2002 | CA2776023A1 Fumaric acid amides |
| 07/18/2002 | CA2725833A1 Spaced drug delivery system |
| 07/18/2002 | CA2697520A1 Use of lyophilised reduced diaminophenothiazines in the treatment of tau mediated neurological disorders |
| 07/18/2002 | CA2436876A1 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 07/18/2002 | CA2436814A1 Intravascular drug delivery device and use therefor |
| 07/18/2002 | CA2436811A1 Use of chromanes for treating parkinson's disease |
| 07/18/2002 | CA2434573A1 Agent for protection against microorganism infection |
| 07/18/2002 | CA2434567A1 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/18/2002 | CA2434274A1 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
| 07/18/2002 | CA2434269A1 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| 07/18/2002 | CA2434152A1 Therapeutic heterocyclic compounds |
| 07/18/2002 | CA2434077A1 Cyclodextrin preparations |
| 07/18/2002 | CA2434015A1 Therapeutic chroman compounds |
| 07/18/2002 | CA2434006A1 Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists |
| 07/18/2002 | CA2434005A1 Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists |
| 07/18/2002 | CA2433997A1 Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists |
| 07/18/2002 | CA2433981A1 Mikanolide derivatives, their preparation and therapeutic uses |
| 07/18/2002 | CA2433960A1 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors |
| 07/18/2002 | CA2433950A1 Therapeutic chromone compounds |
| 07/18/2002 | CA2433813A1 Metabolic controlled fermentation process for carbamoyl tobramycin production |
| 07/18/2002 | CA2433723A1 Chemical derivatives and their use as anti-telomerase agent |
| 07/18/2002 | CA2433720A1 An improved process for preparing pure ondansetron hydrochloride dihydrate |
| 07/18/2002 | CA2433713A1 Preventives for arthritis |
| 07/18/2002 | CA2433656A1 Hormone replacement therapy method and its administration form |
| 07/18/2002 | CA2433653A1 Regulation of lipids and/or bone density and compositions therefor |
| 07/18/2002 | CA2433652A1 Active metabolite of antifungal compound |
| 07/18/2002 | CA2433623A1 Pyridine derivatives useful as cyclooxygenase inhibitor |
| 07/18/2002 | CA2433451A1 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| 07/18/2002 | CA2433449A1 Metabolic gene polynucleotides and polypeptides and uses thereof |
| 07/18/2002 | CA2433084A1 1-(2-methoxybenzyl)-3-benzhydrylpiperazines as tachykinin antagonists |
| 07/18/2002 | CA2433070A1 Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection |
| 07/18/2002 | CA2433066A1 Novel multi-ring organic compounds for regulating gut motility and food intake |
| 07/18/2002 | CA2432883A1 Antigenic ck-18 compounds for therapy and diagnosis and methods for using same |
| 07/18/2002 | CA2432350A1 Method for inhibiting the expression of a target gene |
| 07/18/2002 | CA2432341A1 Method for inhibiting the expression of a target gene and medicament for treating a tumor disease |
| 07/18/2002 | CA2432319A1 Pulmonary delivery of polyene antifungal agents |
| 07/18/2002 | CA2432114A1 4-(hetero)aryl substituted indolinones |